Vaxcyte, Inc. (PCVX) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2021)
PCVX's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
PCVX Revenue Analysis (2017–2025)
As of March 1, 2026, Vaxcyte, Inc. (PCVX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, PCVX's historical revenue data shows various trends over time.
Revenue diversification analysis shows PCVX's business is primarily driven by Pneumococcal Conjugate Vaccine (100%). With over half of revenue concentrated in Pneumococcal Conjugate Vaccine, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BNTX (+3.7% YoY), MRNA (-56.1% YoY), and CDTX (-100.0% YoY). Compare PCVX vs BNTX →
Peer Comparison
Compare PCVX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PCVXCurrent | $0 | - | - | - | |
| BNTX | $2.8B | +3.7% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| CDTX | $1M | -100.0% | -42.9% | -13811.9% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-923,675,000 | - |
| 2024 | $0 | - | $0 | - | $-569,546,000 | - |
| 2023 | $0 | - | $0 | - | $-468,041,000 | - |
| 2022 | $0 | - | $0 | - | $-232,256,000 | - |
| 2021 | $0 | - | $0 | - | $-103,670,000 | - |
| 2020 | $0 | - | $-1,405,000 | - | $-89,581,000 | - |
| 2019 | $0 | - | $-1,232,000 | - | $-54,153,000 | - |
| 2018 | $0 | - | $-1,037,000 | - | $-35,533,000 | - |
| 2017 | $0 | - | $0 | - | $-17,833,000 | - |
See PCVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCVX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PCVX vs AGIO
See how PCVX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PCVX's revenue growth accelerating or slowing?
PCVX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is PCVX's long-term revenue growth rate?
Vaxcyte, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is PCVX's revenue distributed by segment?
PCVX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.